These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32076805)

  • 1. Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
    Wang Y; Lipner SR
    Arch Dermatol Res; 2020 Oct; 312(8):581-586. PubMed ID: 32076805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efinaconazole and Tavaborole.
    Poulakos M; Grace Y; Machin JD; Dorval E
    J Pharm Pract; 2017 Apr; 30(2):245-255. PubMed ID: 26873506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
    Vlahovic TC; Coronado D; Chanda S; Merchant T; Zane LT
    J Drugs Dermatol; 2016 Jan; 15(1):89-94. PubMed ID: 26741386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis.
    Adigun CG; Vlahovic TC; McClellan MB; Thakker KD; Klein RR; Elstrom TA; Ward DB
    J Drugs Dermatol; 2016 Sep; 15(9):1116-20. PubMed ID: 27602975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical and device-based treatments for fungal infections of the toenails.
    Foley K; Gupta AK; Versteeg S; Mays R; Villanueva E; John D
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012093. PubMed ID: 31978269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on tavaborole for the treatment of onychomycosis.
    Jinna S; Finch J
    Drug Des Devel Ther; 2015; 9():6185-90. PubMed ID: 26640371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.
    Zane LT; Plattner J; Chanda S; Coronado D; Merchant T; Alley MR; Gupta AK
    Drugs Today (Barc); 2015 Oct; 51(10):599-607. PubMed ID: 26583302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
    Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R
    J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
    Toledo-Bahena ME; Bucko A; Ocampo-Candiani J; Herz-Ruelas ME; Jones TM; Jarratt MT; Pollak RA; Zane LT
    J Drugs Dermatol; 2014 Sep; 13(9):1124-32. PubMed ID: 25226015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal agents for onychomycosis: new treatment strategies to improve safety.
    Zane LT; Chanda S; Coronado D; Del Rosso J
    Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tavaborole - a treatment for onychomycosis of the toenails.
    Gupta AK; Versteeg SG
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1145-52. PubMed ID: 27347905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
    Rosen T; Stein Gold LF
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S51-5. PubMed ID: 27074700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
    Gupta G; Foley KA; Gupta AK
    Skin Therapy Lett; 2015 Nov; 20(6):6-9. PubMed ID: 27224843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK; Daigle D
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):735-42. PubMed ID: 24894552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration.
    Wang Y; Lipner SR
    J Dermatolog Treat; 2021 Nov; 32(7):783-787. PubMed ID: 31865826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tavaborole 5% solution for onychomycosis.
    Gupta AK; Daigle D; Abramovits W
    Skinmed; 2015; 13(1):55-8. PubMed ID: 25842473
    [No Abstract]   [Full Text] [Related]  

  • 17. Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi.
    Saunders J; Maki K; Koski R; Nybo SE
    J Pharm Pract; 2017 Dec; 30(6):621-630. PubMed ID: 27488125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis.
    Markinson B; Ghannoum M; Winter T; Rycerz A; Rock F; Gupta AK
    J Am Podiatr Med Assoc; 2018 Jan; 108(1):12-19. PubMed ID: 29547036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tavaborole for the treatment of onychomycosis.
    Elewski BE; Tosti A
    Expert Opin Pharmacother; 2014 Jul; 15(10):1439-48. PubMed ID: 24856836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis.
    Gupta AK; Venkataraman M; Shear NH; Piguet V
    Dermatol Ther; 2020 Jul; 33(4):e13613. PubMed ID: 32418289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.